共 50 条
- [31] VALUE AND RISK OF CLASS-I AND CLASS-III ANTIARRHYTHMIC DRUGS PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1994, 17 (03): : 467 - 472
- [34] EFFECT OF CLASS-I ANTIARRHYTHMIC AGENTS ON SLOW CA-2+ CHANNELS OF MYOCARDIAL-CELLS JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1988, 52 (03): : 238 - 242
- [35] COMPARISON OF THE CLINICAL EFFECTS OF CLASS-I ANTIARRHYTHMIC AGENTS ON PREMATURE VENTRICULAR CONTRACTIONS IN RELATION TO THE COUPLING INTERVAL CURRENT TOPICS IN ANTIARRHYTHMIC AGENTS: MODE OF ACTION AND CLINICAL USAGE, 1989, 56 : 287 - 288
- [37] PHARMACOKINETIC STUDY OF RECAINAM, A NEW CLASS-I ANTIARRHYTHMIC AGENT CLINICAL RESEARCH, 1987, 35 (01): : A9 - A9
- [38] ANTIARRHYTHMIC VERSUS ANTIFIBRILLATORY ACTIONS - INFERENCE FROM EXPERIMENTAL STUDIES AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (16): : F25 - F44
- [39] ELECTROPHYSIOLOGIC PROPERTIES OF RECAINAM, A NEW CLASS-I ANTIARRHYTHMIC AGENT CLINICAL RESEARCH, 1986, 34 (02): : A322 - A322
- [40] FOCUS ON MORICIZINE - A NEW PHENOTHIAZINE CLASS-I ANTIARRHYTHMIC AGENT HOSPITAL FORMULARY, 1990, 25 (08): : 841 - 845